Research & Development Projects
Bioproperties' success as a major producer of live vaccines is attributable in large measure to strong collaborative arrangements with the major research institutions in Australia. Bioproperties has established flexible, focused and highly productive relationships with numerous universities and government agencies who share its vision. This leveraged research is conducted with scientific teams, selected for either their core expertise in particular organisms or for their institutional capabilities.
Bioproperties is also a core member of the CRC for Poultry.
Bioproperties' success rate in getting concepts through to marketed vaccines is greater than 95%. As a result, Bioproperties has a suite of fourteen poultry vaccines on the market. In 2003, 2004, 2005, 2006 & 2007, a new vaccine was registered each year (Eimeriavax 4m, Vaxsafe® IBD, Vaxsafe® ND, Vaxsafe® IB & Vaxsafe® ST respectively).
The continued focus on R&D means Bioproperties has a strong R&D pipeline with products being developed for the poultry, swine, cattle and sheep industries. Four of these are at late stage development and six are in early R&D. The ten-year projection for R&D is that a new product will be registered on a yearly basis.